CERo Therapeutics Holdings Inc

CERO

Company Profile

  • Business description

    CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

  • Contact

    201 Haskings Way
    Suite 230
    South San FranciscoCA94080
    USA

    T: +1 650 407-2376

    https://www.cero.bio

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    8

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.702.300.03%
CAC 407,766.7143.240.56%
DAX 4024,206.91133.240.55%
Dow JONES (US)44,280.79125.57-0.28%
FTSE 1008,854.1847.650.54%
HKSE24,148.07260.241.09%
NASDAQ20,440.7928.270.14%
Nikkei 22539,688.81101.130.26%
NZX 50 Index12,859.0294.070.74%
S&P 5006,231.571.590.03%
S&P/ASX 2008,590.701.400.02%
SSE Composite Index3,497.4824.350.70%

Market Movers